VANCOUVER, BC and LAS VEGAS, March 9, 2021 /PRNewswire/ – (CSE: OVAT) (OTCQB: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”), a topical and transdermal cannabis product development company with a patented skin delivery technology and backed by over twenty years of research and development, reports that sales in January 2021 through its licensee in Nevada outperformed the previous month (December 2020) by over 70%. January sales were also the highest since February 2020. Ovation earns royalty income from these sales.
“We are thrilled to report that our royalty income for January resulted in the highest increase in the last twelve months. We believe this represents the beginning of a big turnaround in the topical cannabis business since the beginning of the pandemic said Terry Howlett, CEO of Ovation Science. He added, “We anticipate sales to continue to grow with the re-opening up of the economy and increased tourism back to Nevada and across the country. The proven effectiveness and subsequent repeat buyers of our topical and transdermal products remains a key driver to our superior performance.” Mr. Howlett added “We continue to be focused on selecting a multi-state operator (MSO) in the United States that can duplicate and surpass the success that we have in Nevada. Although all businesses were affected due to the unprecedented lockdowns, we are pleased with the strong start to the new year.”
Ovation’s topicals, backed by over 20 years of R&D, are cannabis-infused creams and lotions that you apply directly to your skin to provide relief . Ovation formulates two types of topicals; ones that remain on the skin to deal with “skin issues” and transdermal creams that allows the CBD (cannabidiol), and/or the THC (tetrahydrocannabinol) to be absorbed through the skin into the bloodstream. Ovation products are powered by Ovation’s Invisicare® drug delivery technology;